Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7502415 | 0.76 | ALDH1A1 (0.41) | KMT2AALDH1A1LMNAMAPTTSHR | |
| SCHEMBL1822806 | 0.72 | LOXL2 (0.48) | POLBALDH1A1LMNAMAPTTSHR | |
| Carbamic Acid SCHEMBL16174718 | 0.70 | ALDH1A1 (0.43) | ALDH1A1MAPTTSHR | |
| SCHEMBL13879701 | 0.69 | MAOA (0.41) | TSHR | |
| SCHEMBL9416346 | 0.67 | ALDH1A1 (0.30) | ALDH1A1LMNAMAPT | |
| SCHEMBL63229 | 0.65 | MEN1 (0.34) | MEN1KMT2APOLBALDH1A1TSHR | |
| SCHEMBL13978035 | 0.64 | MME (0.31) | — | |
| SCHEMBL31143050 | 0.64 | TSHR (0.43) | ALDH1A1TSHR | |
| SCHEMBL29170291 | 0.64 | CYP2D6 (0.35) | TSHR | |
| SCHEMBL899244 | 0.64 | TSHR (0.30) | ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802936-B2 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-20090111183-A1 | Ketone Ligands for Modulating the Expression of Exogenous Genes Via An Ecdysone Receptor Complex | RHEOGENE, INC. | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111183-A1 | Ketone Ligands for Modulating the Expression of Exogenous Genes Via An Ecdysone Receptor Complex | ESRRB, ESRRA, KDELR1 | MEN1 4172/4885KMT2A 1936/4885POLB 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.